Johnson & Johnson deserves more credit for another healthy quarter and strong guidance The new year has been tough on pharmaceutical stocks, including JNJ. But it should not be read as an indictment on the company's operations.
from Top News and Analysis (pro)
via By Anand Gupta
from Top News and Analysis (pro)
via By Anand Gupta
Tags
Finance and Accounting Blogs
Financial Blogs
Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
Mr. Anand Gupta
the anand gupta show
Top News and Analysis (pro)